Scilex Holding announced that the U.S. Patent and Trademark Office has issued a second new patent, No. 11,786,455, further strengthening the Company’s intellectual property position and coverage for its lead commercial product, ZTlido 1.8%, which will expire in 2031. The Patent, titled “Non-aqueous Patch,” covers a non-aqueous lidocaine patch with certain specifications, as well as a method of relieving pain through the application of a non-aqueous lidocaine-containing patch. These two new issued patents No. 11,786,455 and No. 11,793,766 will be listed in the U.S. Food and Drug Administration’s Orange Book in connection with ZTlido.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SCLX:
- Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch
- Scilex announces issuance of new patent in U.S. for ZTlido
- Scilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch
- Scilex announces positive Type C meeting with FDA, to file NDA for SP-102
- Scilex announces new data from deeper skin penetrating studies on SP-103